Quantcast
Last updated on April 18, 2014 at 12:57 EDT

Latest American Society of Hematology Stories

2012-04-09 02:24:20

WASHINGTON, April 9, 2012 /PRNewswire-USNewswire/ -- A novel anti-leukemia compound with little toxicity successfully treated zebrafish with T-cell acute lymphoblastic leukemia (T-ALL), suggesting its potential to become a new highly targeted therapy for humans - even those resistant to conventional therapies - according to results from a study published online today in Blood, the Journal of the American Society of Hematology (ASH). T-ALL is a cancer of the white blood cells in which genetic...

2012-02-21 11:00:00

WASHINGTON, Feb. 21, 2012 /PRNewswire-USNewswire/ -- ASH is encouraged by the steps FDA is taking to alleviate drug shortages that have significantly affected so many patients with hematololgic malignancies under our members' care. The measures announced today are consistent with the Society's recommendations to FDA, Congress, and the Obama Administration to expand the agency's authority to prevent drug shortages by requiring manufacturers to provide early notification of impending...

2012-02-16 10:59:00

As the world´s largest professional society concerned with the causes and treatment of blood disorders, many of ASH's more than 16,000 members are on the front lines of dealing with the country´s severe shortage of methotrexate, a drug critical in the treatment of children with acute lymphocytic leukemia (ALL). This morning the Food and Drug Administration (FDA) reported that two manufacturers plan additional releases at the end of this week, at the end of February, and continuing...

2012-02-15 13:02:00

WASHINGTON, Feb. 15, 2012 /PRNewswire-USNewswire/ -- As the world's largest professional society concerned with the causes and treatment of blood disorders, many of our more than 16,000 members are on the front lines of dealing with the country's severe shortage of methotrexate, a drug critical in the treatment of children with acute lymphocytic leukemia (ALL). This morning the Food and Drug Administration (FDA) reported that two manufacturers plan additional releases at the end of this week,...

2012-01-26 12:42:13

The American Society of Hematology (ASH), the world´s largest professional society concerned with the causes and treatment of blood disorders, today issued a policy statement opposing mandatory screening of athletes for sickle cell trait as a prerequisite to athletic participation and urging athletics programs to adopt universal preventive interventions in their training programs to protect athletes from exertion-related illness and death. ASH´s position is in direct contrast to a...

2012-01-26 08:03:00

WASHINGTON, Jan. 26, 2012 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH), the world's largest professional society concerned with the causes and treatment of blood disorders, today issued a policy statement opposing mandatory screening of athletes for sickle cell trait as a prerequisite to athletic participation and urging athletics programs to adopt universal preventive interventions in their training programs to protect athletes from exertion-related illness...

2011-12-15 15:20:00

NORWALK, Conn., Dec. 15, 2011 /PRNewswire/ -- UBM Medica's CancerNetwork, a leading website for oncology news, reviews, and perspectives, is showcasing extensive and carefully selected coverage of this past week's 2011 American Society of Hematology (ASH) meeting in San Diego, California, the largest annual meeting for practicing hematologists in the U.S. (Photo: http://photos.prnewswire.com/prnh/20111215/SF23864LOGO ) Key reports by CancerNetwork editors on several pivotal...

2011-12-12 16:45:00

SAN DIEGO, Dec. 12, 2011 /PRNewswire/ -- A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center. Jakubowiak will present final results of the phase I-II study on Dec. 12, 2011, at the American...

2011-12-12 16:00:00

- Significant and durable responses in anemia, splenomegaly and constitutional symptoms reported - - Well tolerated for dosing periods up to and exceeding two years - - MRI results confirm meaningful improvements in splenomegaly - MISSISSAUGA, ON, Dec. 12, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated results from the ongoing Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results are being...

2011-12-12 15:41:19

Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology. An estimated 90,000 to 100,000 Americans are affected each year by SCD, a serious disorder that causes normal red blood cells to become rigid and form in a crescent...